Related Experiment Video

Updated: Jul 12, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force

S Gauthier1, J Alam, H Fillit

  • 1Serge Gauthier, McGill Center for Studies in Aging, Verdun QC, Canada, serge.gauthier@mcgill.ca.

The Journal of Prevention of Alzheimer'S Disease
|May 8, 2019
PubMed

Insights

Combination therapy is crucial for Alzheimer's disease (AD) treatment. Experts agreed that targeting multiple pathways and global collaboration are vital for developing effective combination therapies for AD.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Trials

Background:

  • Alzheimer's disease (AD) treatment currently lacks a definitive cure.
  • Combination therapy, targeting multiple disease mechanisms, is a promising avenue for AD.
  • The European Union-North American Clinical Trials in Alzheimer's Disease (EU/US CTAD) Task Force convened to address challenges in AD combination therapy development.

Purpose of the Study:

  • To discuss the scientific, regulatory, and logistical challenges in developing combination therapies for Alzheimer's disease.
  • To review current efforts and strategies to overcome these developmental hurdles.
  • To foster consensus on the future direction of AD combination therapy research.

Main Methods:

  • The study is based on discussions and agreements from the EU/US CTAD Task Force meeting in October 2018.
  • Expert consensus was reached through collaborative deliberation among Task Force members.
  • The focus was on identifying key areas for advancement in AD combination therapy.

Main Results:

  • Unanimous agreement that successful Alzheimer's disease treatment will likely require combination therapy approaches.
  • Recognition that these therapies must target multiple mechanisms and pathways involved in AD.
  • Identification of the critical need for global collaboration and data sharing to accelerate therapeutic development.

Conclusions:

  • Combination therapy is essential for effective Alzheimer's disease treatment.
  • Multifaceted approaches targeting various biological pathways are necessary.
  • International cooperation and resource sharing are paramount to expedite the development of novel AD therapies.

Keywords:
Alzheimer’s diseaseamyloidtautherapeuticstrial design

More Related Videos

Transcranial Pulse Stimulation for Alzheimer's Patients06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-145105:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...